Oliver Manzke, MD
Incyte Corporation · Celgene Corporation
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Oliver Manzke, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:33 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT05429268 · Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)Incyte Corporation · active not recruiting · Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma · study director
- Ph1/Ph2NCT04809467 · A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)Incyte Corporation · terminated · Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma · study director
- N/ANCT02341781 · Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib TreatmentCelgene · completed · Lymphoma, Mantle-Cell · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:33 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.